Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
MARA Rating in the Workflow: How Market Access & BD Teams Use It to Make Better Asset Calls (MARA Rating stands for Market Access Risk Assessment Rating.) Most valuations overweight
Independent MARA® Ratings quantify HTA reimbursement risk for pharma assets. 5-year 97% precision across 10 domains. Request your report today. MARA Rating Insight Since 2020, assets averaging a 2.9 Comparator Selection score sailed
Brensocatib, poised for its first FDA decision in non-cystic fibrosis bronchiectasis, shows clear clinical benefits but faces major U.S. market access challenges. We examine Phase 3 ASPEN trial results, safety
Every payer’s checklist is different. This week: Health-Related Quality of Life—how patient experience shapes coverage. MARA Rating Insight: Since 2020, drugs averaging a 2.8 HRQoL score secured reimbursement far more often than those
An overview of how different payers prioritize safety and tolerability profiles when assessing new therapies. MARA Rating Insight Since 2020, assets averaging a 3.3 Safety score cleared HTA hurdles more often than those
A concise overview of the essential Health Technology Assessment domains every drug developer must address. Use this checklist to design and execute development programs that directly address payer needs across
Market Access Risk Assessment MARA Rating Company Obesity drives ≈ $173 billion in direct U.S. medical costs each year (2019 USD). Four next‑generation pipeline assets—Survodutide, Retatrutide, Orforglipron and the amylin/GLP‑1 co‑formulation Cagrilintide + Semaglutide (“CagriSema”)—promise weight‑loss efficacy
Use this checklist to rapid-fire your due diligence – ensure each asset in your portfolio meets critical payer evidence expectations across all ten domains. The 10 Critical P&R Due Diligence
Breaking the Bias: Why Market-Access Teams Must Avoid Common Thinking Traps in Pharma Acquisitions Many M&A teams do not pay enough attention to market-access risks. Yet simple thinking errors on
MARA Rating Insight Since 2020, assets averaging a 3.1 Cost-Effectiveness score sailed through HTA evaluations, while those at just 1.96 were far more likely rejected. That 1.14-point gap often determines whether payers call your